LTBP1 and systemic sclerosis: In conclusion, our results build on the existing literature, confirming the involvement of pro‐inflammatory mechanisms in SSc‐related ILD (Type 1 Interferon, CX3CL1, CCL2), as well as pro‐fibrotic (CXCL17, THBS, LTBP1).